Not Yet RecruitingNot Applicable

Dural Venous Sinus Stent in Idiopathic Intracranial Hypertension

Egypt40 participantsStarted 2025-03-01

Plain-language summary

This study aims to identify clinical determinants and factors that predict outcome including primary outcome and secondary outcome depending on factors in individual patients with Idiopathic intracranial hypertension treated by Dural venous sinus stenting.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signs and symptoms of increased intracranial pressure: Headaches, nausea, vomiting, visual changes, and papilledema.
✓. No localizing or focal neurologic signs: Except for possible unilateral or bilateral VI nerve paresis.
✓. Elevated cerebrospinal fluid (CSF) pressure: Without cytologic or chemical abnormalities.
✓. No etiology for increased intracranial pressure: On neuroimaging findings.

Exclusion criteria

✕. Age less than or equal to 18 years.
✕. severe allergic reaction to iodine contrast or chronic Kidney disease.
✕. contraindication to general anesthesia or antiplatelet anticoagulants, Hemorrhagic Diathesis
✕. patients with secondary causes of intracranial hypertension: Dural arteriovenous fistula or other arteriovenous lesion affecting cortical venous flow.
✕. pregnancy.

What they're measuring

change in headache impact scale(HIT-6)

Timeframe: 3, 6 months

Papilledema Friesen grading scale

Timeframe: 3 months and 6 months

Visual filed Assessment Perimetry

Timeframe: 3,6 months

Changes in other symptoms tinnitus, abducent nerve palsy and Transient visual Obsecuration

Timeframe: 3,6 months

Trial details

NCT IDNCT06833424

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-01

Contact for this trial

Mohamed zayed Zayed, master degree

+201098099043 mzayeds1206@gmai.com

View on ClinicalTrials.gov More Idiopathic Intracranial Hypertension (IIH) trials